{
  "kind": "treatment",
  "slug": "mesoridazine-serentil",
  "type": "antipsychotic",
  "name": "Mesoridazine (Serentil)",
  "summary": "A phenothiazine-class typical antipsychotic once used for schizophrenia, withdrawn due to cardiac safety concerns.",
  "description": "Mesoridazine is a piperidine phenothiazine antipsychotic indicated for the treatment of schizophrenia. It is a metabolite of thioridazine and works primarily by antagonizing dopamine D2 receptors, reducing positive symptoms of psychosis. It was withdrawn from the U.S. market in 2004 due to risk of QT prolongation and serious ventricular arrhythmias, including torsades de pointes.",
  "category": "medications/antipsychotics",
  "tags": [
    "typical antipsychotic",
    "phenothiazine",
    "withdrawn",
    "schizophrenia"
  ],
  "metadata": {
    "drug_classes": [
      "Typical Antipsychotic",
      "Phenothiazine"
    ],
    "therapeutic_categories": [
      "Psychotic Disorders"
    ],
    "mechanism_categories": [
      "Dopamine Blocker",
      "Alpha Blocker",
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Serentil"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult"
    ],
    "treatment_duration": [
      "Long-term (historical use)"
    ],
    "specialty_areas": [
      "Psychiatry"
    ],
    "fda_approval_year": 1970
  },
  "clinical_metadata": {
    "primary_indications": [
      "Psychosis"
    ],
    "off_label_uses": [],
    "contraindications": [
      "History of QT prolongation or arrhythmias",
      "Concomitant use of other QT-prolonging drugs",
      "Severe CNS depression",
      "Coma"
    ],
    "monitoring_required": [
      "ECG",
      "Electrolytes",
      "Extrapyramidal symptoms"
    ],
    "efficacy_rating": {
      "schizophrenia": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "mesoridazine",
      "serentil",
      "phenothiazine",
      "typical antipsychotic"
    ],
    "synonyms": [
      "mesoridazine besylate"
    ],
    "common_misspellings": [
      "mesoridazin",
      "serantil"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Schizophrenia (historical use)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Antagonizes postsynaptic dopamine D2 receptors in the mesolimbic system, reducing positive symptoms of psychosis. Also has alpha-adrenergic blocking and anticholinergic effects."
    },
    {
      "type": "dosing",
      "adult": {
        "usual_range": "50â€“400 mg/day in divided doses",
        "max": "400 mg/day"
      },
      "geriatric": "Lower initial doses recommended",
      "hepatic_impairment": "Use caution",
      "renal_impairment": "Use caution"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 10 mg, 25 mg, 50 mg, 100 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Gradual improvement in psychotic symptoms over several days to weeks."
    },
    {
      "type": "adverse_effects",
      "common": [
        "drowsiness",
        "dry mouth",
        "constipation",
        "blurred vision",
        "orthostatic hypotension"
      ],
      "less_common": [
        "extrapyramidal symptoms",
        "weight gain",
        "hyperprolactinemia"
      ],
      "serious": [
        "QT prolongation",
        "torsades de pointes",
        "sudden cardiac death",
        "neuroleptic malignant syndrome"
      ]
    },
    {
      "type": "warnings",
      "black_box": "Increased mortality in elderly patients with dementia-related psychosis.",
      "other": [
        "Risk of QT prolongation and torsades de pointes",
        "Withdrawn from the U.S. market in 2004 due to cardiac safety concerns"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Other QT-prolonging drugs",
          "risk": "Additive risk of arrhythmias",
          "action": "Avoid combination"
        },
        {
          "with": "CNS depressants",
          "risk": "Increased sedation",
          "action": "Use caution"
        },
        {
          "with": "Antihypertensives",
          "risk": "Additive hypotensive effects",
          "action": "Monitor blood pressure"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "ECG before and during treatment",
        "Electrolyte levels (potassium, magnesium)",
        "Signs of extrapyramidal symptoms"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if benefits outweigh risks",
      "lactation": "Excreted in breast milk; not recommended",
      "pediatrics": "Safety and efficacy not established",
      "geriatrics": "Increased sensitivity to adverse effects"
    },
    {
      "type": "tapering",
      "text": "Gradually reduce dose to avoid withdrawal dyskinesia or rebound psychosis."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Metabolite of thioridazine with similar efficacy and safety profile",
        "Main reason for discontinuation was cardiac arrhythmia risk",
        "Now primarily of historical and academic interest"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "FDA Drug Withdrawal Notice",
          "url": "https://www.fda.gov/"
        },
        {
          "label": "Mesoridazine Clinical Data",
          "url": "https://pubmed.ncbi.nlm.nih.gov/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Mesoridazine (Serentil): Historical Antipsychotic",
    "description": "Mesoridazine (Serentil) is a phenothiazine antipsychotic once used for schizophrenia, withdrawn from the market due to cardiac risks."
  }
}
